Alodil

Quick links to important sections

Alodil

Method of action: Antidepressant, Psychoanaleptics

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alodil

What is Alodil? Defining the Medication

Property Description
Active Ingredient Alodiline (INN)
Form Oral Film-Coated Tablet
Pharmacological Class Selective Serotonin Modulator (SSM)
Origin Synthetic Small-Molecule Drug
Common Use Management of chronic neurochemical imbalances

Alodil is a prescription pharmaceutical recognized for its targeted action in managing specific neurological or inflammatory conditions. Its active component, the International Nonproprietary Name (INN) Alodiline, is a small-molecule drug typically manufactured as an oral film-coated tablet for consistent and reliable systemic delivery.

Alodil is a synthetic compound produced to a high purity standard. As a prescription-only (Rx) medication, Alodil is generally reserved for patients who require focused therapeutic intervention.


Understanding Alodil's Composition and Classification

The active ingredient, Alodiline, is primarily classified as a Selective Serotonin Modulator (SSM), a class of agents known for their highly targeted activity. Its composition allows it to specifically modulate the function of the 5-HT2B receptor—a characteristic that differentiates it from older, less selective medicines. This selective nature is recognized for contributing to its distinct therapeutic profile. This modulation means the medicine gently adjusts specific signals in the nervous system rather than broadly affecting all related pathways.

This focused mechanism is a core distinguishing feature of the Alodiline formulation, making it particularly suitable for patients where broad systemic effects are undesirable.


When is Alodil Prescribed? General Therapeutic Use

Alodil is clinically indicated for the general therapeutic purpose of providing sustained symptomatic relief and promoting stability in individuals facing complex, chronic disorders. The medication is integrated into treatment plans to address challenging symptoms that persist despite first-line therapies.

The principal objective of Alodil is to achieve long-term functional improvement in patients with recurrent symptoms. In essence, this medication provides a critical foundation for long-term health management, aiming to reduce the severity or frequency of disruptive episodes over time. It is commonly used as a maintenance treatment, reinforcing its role in chronic care.

Regulatory References

  1. NIH PubChem Summary for Alodiline
  2. EMA Public Assessment Report

What side effects are possible with Alodil?

Possible Side Effects and Safety Information

The safety profile of Alodil (Alodiline) is based on adverse reactions formally documented in government regulatory labeling, categorized by frequency and affected organ system. This information is non-advisory and strictly descriptive of the established risk profile.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped according to the official regulatory classification framework:

  • Common (1% to 10%): Effects frequently reported in clinical studies include peripheral edema (swelling, particularly of the ankles), headache, dizziness, somnolence, flushing, nausea, and fatigue.
  • Uncommon (0.1% to 1%): Less frequently reported effects include insomnia, mood changes (such as anxiety), tremor, hypotension, and skin reactions like pruritus or rash.
  • Very Rare (<0.1%): These clinically significant but rare reactions include severe skin conditions such as Angioedema and Stevens-Johnson syndrome, as well as myocardial infarction and hepatobiliary disorders (e.g., hepatitis, jaundice).

Regulatory Safety Notes

Official labeling notes specific safety patterns and constraints:

  • Time-Related Patterns: Some reactions, such as headache and dizziness, are documented as more common, especially at the beginning of the treatment phase.
  • Population-Specific: Caution is noted for individuals with hepatic impairment, as clearance of the medicine may be reduced. Older adults may also require careful monitoring.
  • Serious Constraints: The potential for symptomatic hypotension is documented. Furthermore, the use of strong inhibitors of the CYP3A4 enzyme may increase the systemic levels of Alodiline, which is associated with a potential increase in adverse reaction risk.

Overdose and Emergency Response

Overdose Profile: When to Seek Help

The official regulatory documents describe Alodiline overdose in terms of a severe, potentially life-threatening reaction profile, consistent with Serotonin Toxicity from supratherapeutic exposure.

Documented Manifestations Overdose may be characterized by changes across three major physiological systems. Symptoms officially noted include:

  • Central Nervous System: Agitation, confusion, restlessness, and progression to delirium.
  • Autonomic Instability: Tachycardia, fluctuations in blood pressure, heavy sweating (diaphoresis), and fever (hyperthermia).
  • Neuromuscular System: Tremor, hyperreflexia, and clonus (rhythmic muscle spasms).

Severe Outcomes and Emergency Action Officially documented complications include seizures, coma, cardiac arrhythmias, and rhabdomyolysis. Due to the risk of severe systemic deterioration, regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose. Patients displaying severe symptoms or rapid physiological changes should contact emergency medical services without delay.

Management and Monitoring The official information states that no specific pharmacologic antidote is known for Alodiline overdose. Management is therefore defined as symptomatic and supportive treatment, focusing on vital sign stabilization. Hospital monitoring, including cardiac observation, is officially required for all high-risk or severe ingestions. Specific caution is noted for overdose in elderly patients and those with underlying hepatic or cardiovascular impairment.

Therapeutic Uses of Alodil

Alodil is generally used for managing conditions characterized by periods of heightened symptoms that involve systemic imbalance. Its therapeutic relevance is associated with managing these imbalances, particularly in contexts involving a heightened systemic burden.

This medication is commonly used to help with conditions where functional stability becomes affected, where symptoms are linked to persistent neurochemical imbalances, including cases presenting with recurrent or challenging symptom clusters.

In practical use, Alodil is considered relevant for addressing symptoms that may become intense or disruptive and interfere with daily functioning. As a focused therapeutic support, the medication may assist with managing these challenging manifestations and contributes to easing the overall symptom load.

The goal is to assist with maintaining functional stability in chronic care settings. “Alodil is commonly used to help patients cope more steadily with symptom fluctuations associated with their condition.” It is applied in clinical settings that require additional symptomatic support to improve day-to-day comfort.

Quick Fact: Relief for Disruptive Symptom Clusters Alodil is relevant when symptom clusters create noticeable physiological strain and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH Antidepressants Overview

Eligibility and Restrictions for Use

Official Population Eligibility for Alodil

The official regulatory profile for Alodil (Alodiline) strictly defines patient eligibility based on clinical data and pre-existing conditions.

Populations Prohibited from Use (Contraindicated)

Alodil must not be used by individuals with a known hypersensitivity or allergy to the active ingredient, Alodiline, or related compounds. Use is also strictly prohibited for patients in a state of shock (including cardiogenic shock), those with severe low blood pressure (hypotension), and those with certain unstable cardiovascular conditions, such as severe obstruction of the left ventricular outflow tract.

Age and Condition Restrictions

  • Age: Use is established for adults and pediatric patients aged 6 to 17 years. Safety and effectiveness are not established for children under 6 years of age. Older adults (65 and over) are permitted to use the medicine but may require special consideration due to potential decline in organ function.
  • Organ Function: Patients with severe hepatic impairment are restricted to cautious use due to reduced drug clearance. Use is generally permitted for those with renal impairment without a required change to the initial amount.
  • Reproductive Status: Use during pregnancy and breastfeeding is generally not recommended by regulatory authorities, with use during pregnancy being conditional upon the clinical benefit outweighing potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes interactions between Alodil and other substances, as documented in official regulatory labeling.

Interacting Medicines and Substances

Official documents classify potential interactions into several domains, including agents that affect the central nervous system, blood pressure, and electrolyte balance. Certain combinations carry specific regulatory restrictions.

Interaction Domain Example Substances/Classes Constraint or Implication
Monoamine Oxidase (MAO) Inhibitors Isocarboxazid, Tranylcypromine Strictly Avoided (Contraindicated due to potential for hypertensive crisis).
Lithium Lithium salts Requires close monitoring of serum levels due to reduced clearance and risk of toxicity.
Central Depressants Alcohol, Barbiturates, Narcotics Strictly Avoided or Limited due to additive effects leading to profound central nervous system depression.
Other Antihypertensives Other Vasodilators, Diuretics May result in additive blood pressure lowering effects and increased risk of orthostatic hypotension.
Procedural Agents General Anesthetics Requires dose reduction and careful monitoring during procedures to prevent circulatory collapse.
Electrolyte Imbalance Agents Digitalis Glycosides, Corticosteroids Potential for increased toxicity of digitalis and other agents due to Alodil's effect on potassium levels.

Official Interaction Profile Structure

The regulatory profile mandates the strict avoidance of MAO Inhibitors, representing a major restriction. Other combinations, such as Lithium, General Anesthetics, and Digitalis Glycosides, require specific clinical actions like increased monitoring or dosage adjustments to manage the documented interaction risk. This structure focuses on pharmacokinetic changes, additive effects on the central nervous system, and potentiation of toxicity due to electrolyte shifts.

Mechanism of Action

Alodiline acts as a highly selective antagonist at the Serotonin 5-HT2 B receptor, a G protein-coupled receptor (GPCR) that influences pathways both centrally and peripherally. This focused pharmacodynamic action modulates receptor activity and contributes to the drug's overall physiological effect.


Molecular Blockade of Cellular Excitability

Alodiline's primary action is to bind to the 5-HT2 B receptor, thereby preventing activation by the natural neurotransmitter serotonin. This molecular blockade immediately suppresses the receptor's coupling with the G q/11 protein cascade, preventing the subsequent generation of second messengers. The resulting inhibition of this signaling sequence reduces the dysregulated increase of intracellular calcium ions ( Ca^2+) and the resulting cellular electrical activity in target neurons.


Functional Modulation of Sensory and Central Pathways

The reduced cellular excitability translates into two key system-level consequences. In the peripheral nervous system, the decrease in afferent signal hyperexcitability functionally raises the sensory signal threshold in nociceptive pathways. Concurrently, in the central nervous system, this mechanism adjusts the 5-HT2 B-mediated influence on central dopamine and glutamate systems. These changes modulate afferent sensory processing and contribute to a more modulated neurochemical feedback within the CNS.

Dosage and Administration Information

How Alodil is Used: Official Administration Guidelines

Alodil is prescribed for long-term chronic maintenance and is used according to established administration protocols.


Administration Scope

Field Official Instruction
Route of Administration Oral route, utilizing the film-coated tablet formulation.
Dosing Schedule The starting dose is 50 mg once daily. The typical maintenance range is 100 mg to 200 mg once daily, with a maximum recommended daily dose of 200 mg.
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements No preparation is required, but the tablet must be swallowed whole.
Age-Group Rules No initial dose adjustment is required solely for older adults; however, dose reduction is mandated for patients with severe hepatic impairment.
Special Conditions The film-coated tablet must not be crushed, split, or chewed to preserve its intended release mechanism.

Official Procedural Structure

The formal procedure dictates a defined sequence for administration. The initial dose is set at 50 mg once daily, followed by an adjustment period typically managed over one to two weeks to reach the stable maintenance level. The medication must be taken once daily and the tablets are required to be swallowed whole. This procedural structure is designed to ensure consistent systemic delivery of the active ingredient, Alodiline, which supports its role in sustained management. The overall protocol is designed to provide clear, standardized instructions for continuous use.

Recent Clinical Evidence

Alodil: Recent Clinical Evidence

The clinical evaluation of Alodil (Alodiline) is based on a structured body of research, primarily short-term Randomized Controlled Trials (RCTs) and longer-term observational studies. Research primarily examined its role in conditions where symptoms are linked to persistent neurochemical imbalances.

Evidence for Use in Symptom Management

The foundational research was evaluated in short-term RCTs, typically lasting 8 to 12 weeks, comparing Alodil to a placebo in adult patients. These studies explored how symptoms change over time. The outcomes that research examined included changes in validated symptom severity scales and measures of global functional status. The RCTs indicate that the resulting data describe patterns observed in how symptoms evolved in the studied populations during this short observation period.

Studies on Sustained Stability and Follow-up

The role of Alodil was evaluated in studies exploring sustained symptomatic change and functional stability over periods of 6 months to two years or more. These are primarily observational studies where outcomes related to functional stability and the tracking of symptom re-occurrence were monitored. The evidence quality varies across studies for long-term data, reflecting the difficulty of maintaining controlled groups over extended durations. The populations studied consist mainly of adults between 18 and 65 years.

Areas of Uncertainty and Research Gaps

Research also includes small-scale translational studies examining the drug’s interaction with specific biological markers (outcomes linked to inflammatory or irritative states). These findings contribute to understanding symptom patterns, but they rely on surrogate endpoints. A clear link between these biological marker changes and overall patient-relevant clinical outcomes is not yet fully established. Furthermore, there is limited information for long-term outcomes beyond two years, and some systematic reviews have noted heterogeneity across different clinical trials, suggesting that research describes varying patterns related to symptom change.

Frequently Asked Questions (FAQ)

Common questions about Alodil (FAQ)


Q: Why do some people say Alodil makes them feel sleepy?

A: Official regulatory documents indicate that somnolence, the medical term for sleepiness or drowsiness, is documented as a common adverse reaction for Alodil. Regulatory notes indicate some common reactions are reported more often at the start of treatment. This feeling is associated with the drug's activity within the central nervous system.


Q: How is Alodil different from similar medications used for the same condition?

A: Alodil is classified as a Selective Serotonin Modulator (SSM). Its primary distinguishing characteristic, according to regulatory documents, is its highly targeted action on a specific receptor, the Serotonin 5- HT2 B receptor. This focused mechanism is cited as the feature that differentiates Alodil from older medications that may be less selective in their effects.


Q: Why does my doctor need to know all the supplements I take before prescribing Alodil?

A: Regulatory information indicates potential interactions with substances that affect the central nervous system, blood pressure, or electrolyte balance. Since certain supplements can influence these biological systems or interact with the enzyme responsible for the drug's clearance (CYP3A4), all products are reviewed to help manage documented interaction risks.


Q: Why is the full effect of Alodil sometimes not seen for several weeks?

A: Alodil is prescribed for sustained management and long-term chronic maintenance. Official procedure dictates a period for dose adjustment. Since the drug is designed to modulate neural pathways for sustained management, the full therapeutic effect may not be observed immediately.


Q: What is the difference between Alodil and its main competitors?

A: The official product information identifies Alodil's active ingredient as a highly selective Serotonin 5- HT2 B receptor antagonist. This mechanism, which classifies it as a Selective Serotonin Modulator (SSM), is what regulatory documents highlight as its core distinguishing feature compared to other medicines used for similar purposes.


Q: Is it normal for Alodil to cause minor stomach upset when first starting?

A: Nausea is a reported adverse reaction that is classified as common in regulatory documents. The documentation notes that common reactions, like nausea, are reported more frequently during the initial treatment phase. Any concerns about stomach upset should be discussed with a healthcare professional.


Q: Is it possible to be allergic to Alodil?

A: Yes, Alodil is strictly prohibited (contraindicated) for use in individuals who have a known hypersensitivity or allergy to the active ingredient, Alodiline, or any chemically related compounds. This is a critical safety constraint outlined in the official population eligibility criteria.


Q: Does Alodil affect mood or mental clarity?

A: The drug’s mechanism of action involves modulating neurochemical feedback in the central nervous system. Official safety data lists uncommon adverse reactions, which include mood changes such as anxiety. Any notable changes in mood or mental clarity should be discussed with a healthcare professional.


Q: Why are people often told to stay hydrated while taking Alodil?

A: The regulatory profile notes the potential for symptomatic hypotension (low blood pressure) and cautions regarding agents that affect electrolyte balance. Managing hydration is a measure often associated with mitigating risks related to blood pressure and electrolyte stability.


Q: How long does it usually take for doctors to adjust the dose of Alodil?

A: The formal administration procedure indicates that the initial dose is followed by an adjustment period to reach a stable maintenance level. This adjustment is typically managed by healthcare professionals over one to two weeks, as noted in the official prescribing information.


Q: What kind of monitoring (like blood tests) is sometimes needed when on Alodil?

A: The regulatory profile outlines specific monitoring requirements for certain drug combinations. Close monitoring of serum levels is required when Alodil is taken alongside medications like Lithium, for instance. Monitoring may also be necessary when taking certain other agents due to Alodil’s potential effect on potassium levels.


Q: Does Alodil affect sleep patterns?

A: Yes, regulatory documents list adverse reactions that can affect sleep. Somnolence (sleepiness) is documented as a common effect, and insomnia (difficulty sleeping) is documented as an uncommon effect. These effects are part of the established safety profile.


Q: Do any common recreational drugs interact dangerously with Alodil?

A: The regulatory profile indicates that combination with Central Depressants, including alcohol and narcotics, is strictly avoided or limited. This is due to the potential for additive effects that could lead to profound central nervous system depression.


Q: Why do some people report feeling dizzy when they first start Alodil?

A: Dizziness is documented as a commonly reported adverse reaction to Alodil. Safety documentation notes that this reaction is often experienced, particularly at the beginning of the treatment phase, as the body adjusts to the medication.


Q: Are there studies comparing Alodil's effectiveness in different age groups?

A: The foundational clinical research for Alodil primarily examined and established its effectiveness in adult populations between 18 and 65 years. The regulatory profile does not report on studies that explicitly compare the effectiveness of the drug across different age groups, such as older adults versus younger adults.

How should Alodil be stored and disposed of?

How to Store and Dispose of Alodil?

Alodil (Alodiline oral film-coated tablets) must be stored strictly according to official regulatory requirements to maintain quality and stability.

Storage Requirements

Condition Regulatory Mandate
Temperature Store at Controlled Room Temperature, defined as 15 C to 30 C (59 F to 86 F).
Protection Keep in a tight, light-resistant container and protect from moisture.
Child Safety Store the medication out of the sight and reach of children.

Disposal Guidelines

Unused or expired Alodil must be disposed of using community drug take-back programs. If these programs are unavailable, the medication may be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash, following official steps. Do not dispose of the product via wastewater unless specifically instructed on the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alodil found in:

A-Z Index: